The Valuation of JUUL Continues to Fall


Currently, the U.S. Food and Drug Administration is conducting a scientific review of JUUL’s Premarket Tobacco Application (PMTA). Billy Gifford, CEO of Altria Group, told analysts that he expects the e-vapor category to continue to undergo a transition period over the next few years as the FDA reviews and makes determinations on the various PMTAs it has received.

For all the latest news from Altria Group, visit